FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113809328> ?p ?o ?g. }

• W2113809328 endingPage "1156" @default.
• W2113809328 startingPage "1153" @default.
• W2113809328 abstract "Objective. Patients may cease therapy with anti-tumour necrosis factor (TNF) agents due to inefficacy at 12 weeks (termed primary non-response) or later. Until now, the extent of this later secondary non-response has not been clearly defined. We followed-up a substantial single-centre cohort to determine kinetics of this secondary loss of response. The licensed dose of 3 mg/kg was used throughout. Methods. Prospective data collection since anti-TNF therapy introduction in 1999 formed the basis of the analysis. Patients with rheumatoid arthritis who received infliximab as their first biologic agent, with at least 2 yrs follow-up were included. All relevant clinical data to calculate DAS-28 score and EULAR response were collected at 3, 6, 9, 12, 18 and 24 months. Reasons for cessation in those patients achieving a EULAR response at 3 months (secondary failures) were determined. Results. Of a total of 309 patients commenced on infliximab, 290 received this as their first biologic agent.; 195 commenced ≥2 yrs ago. Efficacy data to identify EULAR responders at 3 months was available in 174 patients. Sixty-seven per cent achieved a ‘moderate’ or ‘good’ EULAR response; 25% failed to achieve a response, 8% developed toxicity within the first 12 weeks. Of the primary responders, over 55% subsequently ceased therapy in the first year, the predominant reason was a secondary loss of response; other reasons included high disease activity despite achieving a definable response, toxicity, and intercurrent illness. Subsequent loss of response in the second year was less pronounced. Conclusions. This study of patients treated in clinical practice with infliximab demonstrated that secondary non-response occurred in around half the patients in the first year. The data highlight the need to continue development of other therapies as well as investigation of the underlying causes of this loss of response." @default.
• W2113809328 created "2016-06-24" @default.
• W2113809328 creator A5018678002 @default.
• W2113809328 creator A5042417820 @default.
• W2113809328 creator A5070464863 @default.
• W2113809328 creator A5072591506 @default.
• W2113809328 date "2007-05-09" @default.
• W2113809328 modified "2023-10-17" @default.
• W2113809328 title "Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders" @default.
• W2113809328 cites W1996437423 @default.
• W2113809328 cites W2005429018 @default.
• W2113809328 cites W2012597670 @default.
• W2113809328 cites W2036135039 @default.
• W2113809328 cites W2074215043 @default.
• W2113809328 cites W2110177517 @default.
• W2113809328 cites W2152348310 @default.
• W2113809328 cites W2319957449 @default.
• W2113809328 cites W2336588424 @default.
• W2113809328 cites W46650105 @default.
• W2113809328 doi "https://doi.org/10.1093/rheumatology/kem075" @default.
• W2113809328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17478470" @default.
• W2113809328 hasPublicationYear "2007" @default.
• W2113809328 type Work @default.
• W2113809328 sameAs 2113809328 @default.
• W2113809328 citedByCount "86" @default.
• W2113809328 countsByYear W21138093282012 @default.
• W2113809328 countsByYear W21138093282013 @default.
• W2113809328 countsByYear W21138093282014 @default.
• W2113809328 countsByYear W21138093282015 @default.
• W2113809328 countsByYear W21138093282016 @default.
• W2113809328 countsByYear W21138093282017 @default.
• W2113809328 countsByYear W21138093282018 @default.
• W2113809328 countsByYear W21138093282019 @default.
• W2113809328 countsByYear W21138093282020 @default.
• W2113809328 countsByYear W21138093282021 @default.
• W2113809328 countsByYear W21138093282022 @default.
• W2113809328 countsByYear W21138093282023 @default.
• W2113809328 crossrefType "journal-article" @default.
• W2113809328 hasAuthorship W2113809328A5018678002 @default.
• W2113809328 hasAuthorship W2113809328A5042417820 @default.
• W2113809328 hasAuthorship W2113809328A5070464863 @default.
• W2113809328 hasAuthorship W2113809328A5072591506 @default.
• W2113809328 hasConcept C126322002 @default.
• W2113809328 hasConcept C141071460 @default.
• W2113809328 hasConcept C188816634 @default.
• W2113809328 hasConcept C2777077863 @default.
• W2113809328 hasConcept C2777138892 @default.
• W2113809328 hasConcept C2777226972 @default.
• W2113809328 hasConcept C2777575956 @default.
• W2113809328 hasConcept C2779134260 @default.
• W2113809328 hasConcept C2780132546 @default.
• W2113809328 hasConcept C71924100 @default.
• W2113809328 hasConcept C72563966 @default.
• W2113809328 hasConceptScore W2113809328C126322002 @default.
• W2113809328 hasConceptScore W2113809328C141071460 @default.
• W2113809328 hasConceptScore W2113809328C188816634 @default.
• W2113809328 hasConceptScore W2113809328C2777077863 @default.
• W2113809328 hasConceptScore W2113809328C2777138892 @default.
• W2113809328 hasConceptScore W2113809328C2777226972 @default.
• W2113809328 hasConceptScore W2113809328C2777575956 @default.
• W2113809328 hasConceptScore W2113809328C2779134260 @default.
• W2113809328 hasConceptScore W2113809328C2780132546 @default.
• W2113809328 hasConceptScore W2113809328C71924100 @default.
• W2113809328 hasConceptScore W2113809328C72563966 @default.
• W2113809328 hasIssue "7" @default.
• W2113809328 hasLocation W21138093281 @default.
• W2113809328 hasLocation W21138093282 @default.
• W2113809328 hasOpenAccess W2113809328 @default.
• W2113809328 hasPrimaryLocation W21138093281 @default.
• W2113809328 hasRelatedWork W1555548379 @default.
• W2113809328 hasRelatedWork W1973470095 @default.
• W2113809328 hasRelatedWork W1976481621 @default.
• W2113809328 hasRelatedWork W1979251453 @default.
• W2113809328 hasRelatedWork W1987798738 @default.
• W2113809328 hasRelatedWork W1993992685 @default.
• W2113809328 hasRelatedWork W2341567294 @default.
• W2113809328 hasRelatedWork W2416182167 @default.
• W2113809328 hasRelatedWork W2463309567 @default.
• W2113809328 hasRelatedWork W4200063390 @default.
• W2113809328 hasVolume "46" @default.
• W2113809328 isParatext "false" @default.
• W2113809328 isRetracted "false" @default.
• W2113809328 magId "2113809328" @default.
• W2113809328 workType "article" @default.